Relapsen = 12 | Remissionn = 14 | P | |
---|---|---|---|
Duration from onset of EGPA (months) | 61.3 ± 100.7 | 75.1 ± 96.4 | NS* |
BVAS at relapse or remission | 14.5 ± 9.5 | 0 ± 0 | < 0.01* |
Prednisolone dose at relapse or remission | 10.4 ± 4.6 | 9.6 ± 7.6 | NS* |
Immunosuppressant use at relapse or remission (%) | 75 | 35.7 | <0.05 |
CYC/AZA/CSA/MTX/RTX | 7/1/1/0/0 | 3/2/0/0/0 | NS‡ |
No. of eosinophils in peripheral blood | 350.8 ± 262.0 | 309.3 ± 273.2 | NS* |
FOXP3+ cells among CD4+ T cells (%) | 0.5 ± 0.4 | 5.8 ± 2.1 | < 0.01† |
IL-10+ cells among CD4+CD25+ T cells (%) | 0.3 ± 0.8 | 10.9 ± 11.4 | < 0.01† |
TGF-β+ among CD4+CD25+ T cells (%) | 0.2 ± 0.7 | 7.4 ± 6.1 | < 0.01† |
IL-2+ among CD4+CD25− T cells (%) | 9.9 ± 14.1 | 32.2 ± 25.3 | < 0.05† |